Table 3 Relationship among PD-L1(22C3), TMB and clinical pathological features in 33 patients with TLS + primary adenocarcinoma of jejunum and ileum

Age(y)

≤ 60

20

3

13

1

7

13

1

>60

13

5

8

4

9

Sex

M

19

8

11

0.486

6

13

1

F

14

4

10

5

9

Tumor site

Jejunum

27

8

19

0.159

10

17

0.637

Ileum

6

4

2

1

5

Tumor size(cm)

≤ 5

23

7

16

0.433

5

18

0.049

>5

10

5

5

6

4

Macroscopic tumor perforation

Yes

2

1

1

1

1

1

1

No

31

11

10

10

21

Differentiation grade

Moderately differentiation

22

8

14

1

5

17

0.078

Poorly differentiation

8

3

5

5

3

Lymphatic invasion

Yes

21

5

16

0.067

6

15

1

No

12

7

5

5

7

Vascular invasion

Yes

10

5

5

0.433

3

7

1

No

23

7

16

8

15

Neural invasion

Yes

22

7

15

0.471

4

18

0.017

No

11

5

6

7

4

Tumor nodules

Yes

11

4

7

1

5

6

0.437

No

22

8

14

6

16

Mucinous component

Yes

7

3

4

0.686

1

6

0.378

No

26

9

17

10

16

T stage

T3

12

4

8

1.000

5

7

0.471

T4

21

8

13

6

15

N stage

N0

22

8

13

1.000

7

15

1.000

N1-3

11

4

7

4

7

M stage

M0

16

8

8

0.157

7

9

0.282

M1

17

4

13

4

13

TNM stage

II

12

5

7

0.716

4

8

1

III-IV

21

7

14

7

14

PD-L1(22C3)

CPS ≥ 1

11

5

6

0.471

CPS<1

22

7

15

MSI-H

Yes

3

3

0

0.04

1

2

1

No

30

9

21

10

20

KRAS mutation

Yes

17

4

13

0.157

5

12

0.721

No

16

8

8

6

10

BRAF mutation

Yes

31

11

20

1

10

21

1

No

2

1

1

1

1

PIK3CA mutation

Yes

1

1

0

0.364

1

0

1

No

32

11

21

11

21